These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

590 related items for PubMed ID: 23110609

  • 1. Insulin detemir: a review of its use in the management of diabetes mellitus.
    Keating GM.
    Drugs; 2012 Dec 03; 72(17):2255-87. PubMed ID: 23110609
    [Abstract] [Full Text] [Related]

  • 2. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K.
    Cochrane Database Syst Rev; 2020 Nov 09; 11(11):CD005613. PubMed ID: 33166419
    [Abstract] [Full Text] [Related]

  • 3. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.
    Clin Ther; 2004 May 09; 26(5):724-36. PubMed ID: 15220016
    [Abstract] [Full Text] [Related]

  • 4. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B, Metzendorf MI, Richter B.
    Cochrane Database Syst Rev; 2021 Mar 04; 3(3):CD013498. PubMed ID: 33662147
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Insulin detemir: a review of its use in the management of type 1 and 2 diabetes mellitus.
    Chapman TM, Perry CM.
    Drugs; 2004 Mar 04; 64(22):2577-95. PubMed ID: 15516157
    [Abstract] [Full Text] [Related]

  • 7. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.
    Health Technol Assess; 2010 Jul 04; 14(36):1-248. PubMed ID: 20646668
    [Abstract] [Full Text] [Related]

  • 8. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study.
    Dornhorst A, Lüddeke HJ, Honka M, Ackermann RW, Meriläinen M, Gallwitz B, Sreenan S, PREDICTIVE Study Group.
    Curr Med Res Opin; 2008 Feb 04; 24(2):369-76. PubMed ID: 18096110
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Defining the role of insulin detemir in Basal insulin therapy.
    Morales J.
    Drugs; 2007 Feb 04; 67(17):2557-84. PubMed ID: 18034591
    [Abstract] [Full Text] [Related]

  • 11. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
    Dornhorst A, Lüddeke HJ, Koenen C, Meriläinen M, King A, Robinson A, Sreenan S, PREDICTIVE Study Group.
    Diabetes Obes Metab; 2008 Jan 04; 10(1):75-81. PubMed ID: 18034846
    [Abstract] [Full Text] [Related]

  • 12. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus.
    Chapman TM, Perry CM.
    BioDrugs; 2005 Jan 04; 19(1):67-9. PubMed ID: 15691219
    [Abstract] [Full Text] [Related]

  • 13. Insulin glargine: a systematic review of a long-acting insulin analogue.
    Wang F, Carabino JM, Vergara CM.
    Clin Ther; 2003 Jun 04; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of the incidence and risk of hypoglycemic coma associated with selection of basal insulin in the treatment of diabetes: a Finnish register linkage study.
    Haukka J, Hoti F, Erästö P, Saukkonen T, Mäkimattila S, Korhonen P.
    Pharmacoepidemiol Drug Saf; 2013 Dec 04; 22(12):1326-35. PubMed ID: 24150837
    [Abstract] [Full Text] [Related]

  • 15. An increased dose of insulin detemir improves glycaemic control and reduces body weight of Japanese patients with diabetes.
    Fujii H, Watanabe Y, Ueki A, Ohno A, Kato M, Kondo K, Takamura H, Takesue M, Nishimura H, Matsuda D, Miyakawa T.
    Int J Clin Pract; 2010 Oct 04; 64(11):1512-1519. PubMed ID: 20678116
    [Abstract] [Full Text] [Related]

  • 16. Daily insulin doses and injection frequencies of neutral protamine hagedorn (NPH) insulin, insulin detemir and insulin glargine in type 1 and type 2 diabetes: a multicenter analysis of 51 964 patients from the German/Austrian DPV-wiss database.
    Laubner K, Molz K, Kerner W, Karges W, Lang W, Dapp A, Schütt M, Best F, Seufert J, Holl RW.
    Diabetes Metab Res Rev; 2014 Jul 04; 30(5):395-404. PubMed ID: 24302583
    [Abstract] [Full Text] [Related]

  • 17. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes.
    Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigsson J.
    Diabet Med; 2007 Jan 04; 24(1):27-34. PubMed ID: 17227321
    [Abstract] [Full Text] [Related]

  • 18. Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial.
    Thalange N, Bereket A, Larsen J, Hiort LC, Peterkova V.
    Diabet Med; 2013 Feb 04; 30(2):216-25. PubMed ID: 23094597
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial.
    Fajardo Montañana C, Hernández Herrero C, Rivas Fernández M.
    Diabet Med; 2008 Aug 04; 25(8):916-23. PubMed ID: 18959604
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.